As molecular testing becomes more widely adopted in the community oncology setting, cancer programs can benefit from access to innovative formats to help ensure that communication and quality patient care standards are maintained. Several innovative ACCC member programs have begun using virtual tumor board models as part of the integration of molecular testing into practice.
The virtual tumor board format enables participation by a variety of providers across a wide geographic area. Members of multidisciplinary teams across sites can join in the virtual discussion of cases and determine treatment—regardless of the physical location of the patient and care team.
Building on interviews with select ACCC member programs, ACCC and our partner organization, the Association for Molecular Pathology (AMP), developed a webinar series focused on virtual molecular tumor boards for lung and breast cancer. The webinar series shown below includes case studies and robust discussions on molecular testing in the community setting.
Presentations feature experts from leading cancer programs:
Eric Duncavage, MD, Washington University School of Medicine, Barnes-Jewish Hospital
Annette S. Kim, MD, PhD, Brigham And Women's Hospital
Molecular biomarker testing is performed more frequently as cancer programs look to offer targeted therapies for lung and breast cancer patients. Hear key takeaways and lessons learned from the ACCC Virtual Molecular Tumor Boards project, including how tumor boards can help to coordinate testing and interpret results. Gain insight on the future of molecular testing for delivery of precision cancer care.
Originally presented July 19, 2017.
Sharon Hunt, MBA
Sanford Cancer Center
It requires a coordinated effort across clinical and administrative teams to successfully implement a genomic tumor board program. Gain strategies to navigate the challenges that may arise while building a tumor board program that will engage clinicians, maximize meaningful participation, and lead to improved patient care.
Originally presented May 22, 2017.
Steven Powell, MD
Sanford Cancer Center
Developing a successful genomic tumor board requires effective engagement strategies to demonstrate value to providers with varying levels of understanding about cancer genomics. Education and outreach tactics must reach clinicians who work in different locations or specialize in treating specific malignancies. Hear how one ACCC-member cancer program’s journey in building a genomic tumor board led to increased engagement and communication across the clinical care team and provided new treatment options for patients with complex cancers.
Originally presented May 16, 2017.
Melissa L. Johnson, MD
Sarah Cannon Research Institute, Tennessee Oncology
Recent advances in lung cancer molecular testing and targeted therapies are leading to greater options for patients, including the approval of multiple agents for the treatment of advanced NSCLC patients with EGFR, ALK, or ROS1 mutations. This webinar will highlight ongoing advances and updates in lung cancer molecular testing and the potential clinical role of emerging agents on the horizon.
Originally presented April 28, 2017.
Olufunmilayo I. Olopade, MD, FACP
The University of Chicago Medicine
As the precision medicine landscape continues to evolve, the relevance of clinical genetics is intersecting with the advancing science of tumor genomic profiling. Gain a greater understanding of the clinical relevance of genetics vs. genomic profiling specific to breast cancer care, and the differences between hereditary/germline vs. somatic mutations.
Originally presented March 24, 2017.
Megan Landsverk, PhD, FACMG
Patricia Crotwell, PhD, FACMG
Sanford Cancer Center
Community cancer programs can expand patient services by including experts in molecular genetics and tumor genomics on their multidisciplinary team. Learn how these professionals contribute to the development of personalized genomic testing, analysis of pharmacogenetic factors to predict cancer prognosis and response to treatment, and the cytogenetic analysis of cancer.
Originally presented on March 16, 2017.
John Maurice, MD
Enza Esposito-Nguyen, RN, MSN, ANP-BC
Lavinia Dobrea, RN, MS, OCN
St. Joseph Hospital of Orange, The Center for Cancer Prevention and Treatment
St. Joseph Hospital of Orange has been on a continuous journey to advance their molecular testing processes in patients with lung cancer. Starting with a project based around the Lean methodology, the thoracic oncology team identified ways to improve tissue acquisition, testing processes, and clinical trial enrollment. Gain insight into their ongoing journey in process improvement and clinical care excellence.
Originally presented on March 13, 2017.
Jeffrey Gregg, MD
Senior Director, Clinical Pathology Director, Molecular Diagnostics Professor of Pathology, Department of Pathology and Laboratory Medicine
University of California, Davis Medical Center
Advances in molecular testing capabilities are leading clinicians to perform genomic profiling to identify potentially actionable targets for treatment. This webinar will provide a broad overview of some recent advances in genomic testing and explain how results may impact treatment decisions on a practical level.
Originally presented on December 14, 2016.
Arvind Chaudhry, MD, PhD, Summit Cancer Centers
V.K. Gadi, MD, PhD, Seattle Cancer Care Alliance
Joseph Kim, MD, Xaphesis
Listen to the discussion on case related topics including triple negative breast cancer, benefits and recommendations for molecular testing, HER2-directed therapies, and more.
Originally presented on October 26, 2016.
Joseph Kim, MD, MPH, MBA, Xaphesis
Annie Chapman, MPH, Seattle Cancer Care Alliance
Eric Duncavage, MD, Washington University in St. Louis
Mark S. Soberman, MD, MBA, FACS, Frederick Regional Health System
In this first webinar of the virtual molecular tumor board series, hear from a multidisciplinary panel on how cancer programs can form valuable relationships with research centers for access to experts to translate the latest developments in molecular testing to appropriate individual patient treatment recommendations. Compare various tumor board models, partnership benefits, and effective practices.
Originally presented on October 20, 2016.